Zacks Research Lowers Forecasted EPS for Integer Holdings Corporation (ITGR) for FY 2022
January 9, 2023
Trending News 🌧️
Integer Holdings ($NYSE:ITGR) Corporation (ITGR) is a publicly traded company on the New York Stock Exchange that provides medical device outsourcing services. Recently, Zacks Research has lowered their forecasted earnings per share (EPS) for Integer Holdings Corporation for fiscal year 2022.
Additionally, the company has experienced increasing competition in the medical device outsourcing market, which has put downward pressure on their profits. The lowered EPS forecast for Integer Holdings is concerning for investors, as it could lead to lower stock prices and decreased dividends for shareholders. Additionally, it could also result in lower future earnings for the company as a whole. Despite this, Integer Holdings still remains an attractive investment opportunity due to its strong balance sheet and its potential for growth in the future. The company is well-positioned to take advantage of any opportunities that arise in the coming years, and investors should remain confident in the long-term prospects of the company.
Market Price
At the time of this news coverage, most of the market response was positive.
However, the stock opened at $69.5 and closed at $67.9, a decrease of 0.8% from prior closing price of 68.5. Their portfolio of services includes the design and manufacture of complex, highly-engineered medical products, such as catheters, stents, and drug-eluting balloons for the interventional cardiovascular, orthopedic, and urology markets. The lowered EPS forecast for FY 2022 means that investors should expect a decrease in profits from the company. This news has caused some concern among current shareholders and potential investors alike, who are now questioning the long-term outlook for the company. Integer Holdings Corporation continues to strive for innovation and the best possible medical devices for their customers. They have taken all necessary steps to ensure their products are of the highest quality and safety standards, and are confident that their current and future products will live up to their customers’ expectations. Although the news of a lower EPS forecast has caused some short-term market movement, Integer Holdings Corporation is still a leader in the medical device manufacturing industry and remains a viable option for investors looking for long-term stability and growth potential. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Integer Holdings. More…
| Total Revenues | Net Income | Net Margin |
| 1.32k | 72.05 | 6.3% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Integer Holdings. More…
| Operations | Investing | Financing |
| 104.03 | -410.47 | 300.46 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Integer Holdings. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 2.74k | 1.38k | 40.9 |
Key Ratios Snapshot
Some of the financial key ratios for Integer Holdings are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 2.1% | -12.1% | 8.2% |
| FCF Margin | ROE | ROA |
| 2.8% | 4.9% | 2.5% |
VI Analysis
Integer Holdings Corporation (INTEGER) is a high-risk investment, based on its VI Risk Rating. The rating takes into account the company’s financial and business fundamentals to give a comprehensive evaluation of its long-term potential. The VI App has detected two risk warnings in the company’s income statement and balance sheet. These warnings suggest that INTEGER may have difficulty meeting its financial obligations and sustaining its current business model. INTEGER’s risk rating can be improved by taking measures to reduce its debt levels and strengthen its cash flow. Additionally, it should focus on improving its customer base, increasing sales, and reducing expenses. Furthermore, INTEGER should look to diversify its income sources and reduce its reliance on any single customer or product line. Investors should take note that INTEGER is a high-risk investment, and should only invest if they are comfortable with the potential for losses. It is important for investors to do their due diligence before investing in INTEGER, as well as understand the risks involved. By registering with VI App, investors can access further information about INTEGER and understand the potential risks associated with the company. More…
VI Peers
The company designs, develops, manufactures, and markets medical devices and services worldwide. Integer’s competitors in the orthopedics industry include Polynovo Ltd, Globus Medical Inc, and Shenzhen Mindray Bio-Medical Electronics Co Ltd.
– Polynovo Ltd ($ASX:PNV)
Polynovo Ltd is a medical device company that designs, manufactures, and markets biodegradable scaffolds for use in tissue regeneration. The company has a market cap of 1.32B as of 2022 and a Return on Equity of -3.08%. Polynovo’s products are used in a variety of applications, including orthopedics, plastic surgery, and wound care. The company’s products are sold in over 30 countries worldwide.
– Globus Medical Inc ($NYSE:GMED)
Globus Medical Inc is a leading musculoskeletal solutions company. They design, develop, manufacture and market a comprehensive line of products for the orthopedic market. Their products are used in a wide variety of procedures, including spine, hip, and extremities. Globus Medical Inc has a market cap of 7.02B as of 2022, a Return on Equity of 7.24%. Globus Medical is committed to helping improve the quality of life for patients with musculoskeletal disorders. Their products are designed to provide solutions that enable patients to return to their active lifestyles.
– Shenzhen Mindray Bio-Medical Electronics Co Ltd ($SZSE:300760)
Shenzhen Mindray Bio-Medical Electronics Co Ltd is a medical device company that manufactures a range of medical devices and equipment. The company has a market capitalization of $366.53 billion as of 2022 and a return on equity of 23.24%. The company’s products are used in a variety of medical applications, including diagnostics, patient monitoring, and imaging.
Summary
Integer Holdings Corporation (ITGR) is a healthcare technology and services company based in Plano, Texas. The company offers a range of products and services that enable healthcare organizations to improve patient care, reduce costs, and improve operational efficiency. Recently, Zacks Research lowered its forecasted earnings per share (EPS) for the company for FY 2022. Despite this news, the company’s stock has remained relatively stable and analysts remain positive on the company’s future prospects.
Integer Holdings is expected to benefit from the increasing demand for its products and services, as well as from its commitment to innovation. Investors should continue to monitor the company’s performance for potential growth opportunities.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
